JP2015517994A - ハロフジノンの剤形およびその使用 - Google Patents

ハロフジノンの剤形およびその使用 Download PDF

Info

Publication number
JP2015517994A
JP2015517994A JP2015503640A JP2015503640A JP2015517994A JP 2015517994 A JP2015517994 A JP 2015517994A JP 2015503640 A JP2015503640 A JP 2015503640A JP 2015503640 A JP2015503640 A JP 2015503640A JP 2015517994 A JP2015517994 A JP 2015517994A
Authority
JP
Japan
Prior art keywords
halofuginone
dosage form
oral dosage
pharmaceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517994A5 (enExample
Inventor
アーネスト ディー． ブッシュ，
アーネスト ディー． ブッシュ，
ダイアン マグワイヤー，
ダイアン マグワイヤー，
マーク ビー． ブラウステイン，
マーク ビー． ブラウステイン，
Original Assignee
ヘイロー セラピューティックス， エルエルシー
ヘイロー セラピューティックス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘイロー セラピューティックス， エルエルシー, ヘイロー セラピューティックス， エルエルシー filed Critical ヘイロー セラピューティックス， エルエルシー
Publication of JP2015517994A publication Critical patent/JP2015517994A/ja
Publication of JP2015517994A5 publication Critical patent/JP2015517994A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015503640A 2012-03-29 2013-03-29 ハロフジノンの剤形およびその使用 Pending JP2015517994A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261617356P 2012-03-29 2012-03-29
US61/617,356 2012-03-29
US201361798784P 2013-03-15 2013-03-15
US61/798,784 2013-03-15
PCT/US2013/034616 WO2013149148A2 (en) 2012-03-29 2013-03-29 Dosage forms of halofuginone and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018191024A Division JP2018203790A (ja) 2012-03-29 2018-10-09 ハロフジノンの剤形およびその使用

Publications (2)

Publication Number Publication Date
JP2015517994A true JP2015517994A (ja) 2015-06-25
JP2015517994A5 JP2015517994A5 (enExample) 2016-03-03

Family

ID=49261398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503640A Pending JP2015517994A (ja) 2012-03-29 2013-03-29 ハロフジノンの剤形およびその使用
JP2018191024A Pending JP2018203790A (ja) 2012-03-29 2018-10-09 ハロフジノンの剤形およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018191024A Pending JP2018203790A (ja) 2012-03-29 2018-10-09 ハロフジノンの剤形およびその使用

Country Status (9)

Country Link
US (2) US20150086627A1 (enExample)
EP (1) EP2830628A4 (enExample)
JP (2) JP2015517994A (enExample)
CN (1) CN104640546A (enExample)
AU (2) AU2013237881B2 (enExample)
CA (1) CA2869054A1 (enExample)
HK (1) HK1206646A1 (enExample)
IL (1) IL234841A0 (enExample)
WO (1) WO2013149148A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335573B2 (en) 2015-12-02 2019-07-02 Cook Medical Technologies Llc Intraperitoneal chemotherapy medical devices, kits, and methods
CN106539754A (zh) * 2016-11-25 2017-03-29 河北科星药业有限公司 氢溴酸常山酮溶液及其制备方法
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
CN109793741B (zh) * 2019-03-11 2021-02-26 中国农业科学院兰州兽医研究所 一种常山酮在制备预防口蹄疫病毒感染的药物中的应用
WO2022040566A1 (en) * 2020-08-21 2022-02-24 The Regents Of The University Of California Methods and uses of halofuginone
CN113880860B (zh) * 2021-12-08 2022-02-22 北京肿瘤医院(北京大学肿瘤医院) 常山酮衍生物及其药物组合物和用途
CN114469956B (zh) * 2022-01-29 2023-07-18 中国科学技术大学 常山酮在治疗和预防动脉粥样硬化性疾病的药物中的应用
CN116392493A (zh) * 2023-02-02 2023-07-07 四川大学华西医院 一种关于天然活性化合物hf诱导atc细胞凋亡的应用
CN119215052B (zh) * 2024-09-03 2025-09-02 南方医科大学南方医院 常山酮在制备治疗异位骨化的药物中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50117913A (enExample) * 1974-02-27 1975-09-16
JPS5732230A (en) * 1980-07-18 1982-02-20 Parke Davis & Co Instetine-soluble capsule
JPH01156929A (ja) * 1987-09-29 1989-06-20 Warner Lambert Co 腸溶製剤の安定化
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
JPH04346930A (ja) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
JP2004155773A (ja) * 2002-10-16 2004-06-03 Takeda Chem Ind Ltd 安定な固形製剤
US20100144766A1 (en) * 2007-01-21 2010-06-10 Mark Pines Composition and method for treating or preventing skeletal muscle fibrosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356634A (en) * 1992-11-13 1994-10-18 Eastman Chemical Company Controlled-release delivery system
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
IL148292A (en) * 2002-02-21 2008-08-07 Shai Yarkoni Stable preparations of lupoginone and other quinazolinone derivatives
ATE425744T1 (de) * 2002-04-29 2009-04-15 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit
WO2004039308A2 (en) * 2002-10-31 2004-05-13 State Of Israel, Ministry Of Agriculture Quinazolinone compositions for regulation of gene expression related to pathological processes
CN100591336C (zh) * 2002-11-08 2010-02-24 汪建平 菱角提取物及其使用方法
US7705049B2 (en) * 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
US20050208134A1 (en) * 2004-02-25 2005-09-22 Shlomo Magdassi Biocompatible polymeric beads and use thereof
US20070281961A1 (en) * 2006-06-05 2007-12-06 Brite Age Modified Compositions And Methods For Enhancing Brain Function
TWI478710B (zh) * 2007-11-30 2015-04-01 Univ California 使用半胱胺產物治療非酒精性脂肪肝炎（ｎａｓｈ）之方法
CN102177152A (zh) * 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50117913A (enExample) * 1974-02-27 1975-09-16
JPS5732230A (en) * 1980-07-18 1982-02-20 Parke Davis & Co Instetine-soluble capsule
JPH01156929A (ja) * 1987-09-29 1989-06-20 Warner Lambert Co 腸溶製剤の安定化
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
JPH04346930A (ja) * 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
JP2004155773A (ja) * 2002-10-16 2004-06-03 Takeda Chem Ind Ltd 安定な固形製剤
US20100144766A1 (en) * 2007-01-21 2010-06-10 Mark Pines Composition and method for treating or preventing skeletal muscle fibrosis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Committee for veterinary medicinal products", EMEA/MRL/741/00-FINAL, JPN6017007158, 2001, pages 7 - 7, ISSN: 0003511978 *
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 9, JPN6017007160, 2003, pages 417 - 425, ISSN: 0003511975 *
BR. VET. J., vol. 145, JPN6017007155, 1989, pages 546 - 551, ISSN: 0003511976 *
J CLIN PATHOL, vol. 38, JPN6017007157, 1985, pages 1321 - 1336, ISSN: 0003511977 *

Also Published As

Publication number Publication date
AU2018200167A1 (en) 2018-02-01
WO2013149148A2 (en) 2013-10-03
JP2018203790A (ja) 2018-12-27
EP2830628A2 (en) 2015-02-04
HK1206646A1 (en) 2016-01-15
WO2013149148A8 (en) 2013-11-14
AU2013237881B2 (en) 2017-10-12
EP2830628A4 (en) 2016-05-25
IL234841A0 (en) 2014-12-31
WO2013149148A3 (en) 2015-04-16
US20150086627A1 (en) 2015-03-26
CA2869054A1 (en) 2013-10-03
AU2013237881A1 (en) 2014-10-16
CN104640546A (zh) 2015-05-20
US20180193276A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
JP2018203790A (ja) ハロフジノンの剤形およびその使用
KR100566701B1 (ko) 고위험의 내당력 장애를 치료하기 위한 알파-글루코시다제억제제의 용도
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP4466370B2 (ja) 過活動膀胱治療剤
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
US20160228388A1 (en) Methods of administering amantadine compositions
CN108012527A (zh) 苯并咪唑衍生物用于夜间酸突破的用途
WO2000000187A1 (fr) Compositions medicinales destinees au traitement de l'insuffisance d'evacuation
JPS61229823A (ja) 脳血管性痴呆における記憶障害治療剤
US20080280944A1 (en) Imidazo[1,2-A]Pyridine Derivatives For The Treatment Of Silent Gastro-Esophageal Reflux
KR100192534B1 (ko) 소마토스타틴 분비증가제와 분비저하 억제제
CN117396202A (zh) 给药方案
JPWO2017199755A1 (ja) 認知症の予防及び／又は治療のための薬剤
JP2010529125A (ja) 胃食道逆流疾患の治療に有用な組成物
US11116751B2 (en) Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
TW202313072A (zh) 檸檬酸鐵之兒科調配物
JP2018052839A (ja) 慢性疼痛治療剤
US20060063842A1 (en) Hypogastric and/or perineal pain-relieving agent
JPWO2000000187A1 (ja) 排出障害治療用医薬組成物
HK1124543A (en) Imidazo[1,2-a]pyridine derivatives for use in the treatment of sleep disturbance due to silent gastro-esophageal reflux
JPWO2001010436A1 (ja) 下部尿路症治療用医薬組成物
HK1243939B (en) Amantadine for improving gait in multiple sclerosis
HK1243939A1 (en) Amantadine for improving gait in multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009